Cary Street Partners Financial LLC Makes New $865,000 Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Cary Street Partners Financial LLC bought a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 1,214 shares of the biopharmaceutical company's stock, valued at approximately $865,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. OFI Invest Asset Management purchased a new position in shares of Regeneron Pharmaceuticals in the 4th quarter worth about $28,000. Rakuten Securities Inc. grew its position in shares of Regeneron Pharmaceuticals by 62.5% during the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock worth $28,000 after buying an additional 15 shares in the last quarter. Avalon Trust Co bought a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter worth about $36,000. Crowley Wealth Management Inc. acquired a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter valued at approximately $36,000. Finally, Private Wealth Management Group LLC lifted its holdings in Regeneron Pharmaceuticals by 260.0% in the fourth quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company's stock worth $38,000 after acquiring an additional 39 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company's stock.

Regeneron Pharmaceuticals Trading Down 3.6 %

Shares of NASDAQ REGN traded down $19.89 during mid-day trading on Friday, hitting $527.78. 1,498,740 shares of the company traded hands, compared to its average volume of 769,971. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 1 year low of $520.50 and a 1 year high of $1,211.20. The stock has a market capitalization of $57.70 billion, a price-to-earnings ratio of 13.79, a PEG ratio of 2.34 and a beta of 0.43. The business has a 50 day moving average of $613.08 and a two-hundred day moving average of $693.43.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing the consensus estimate of $8.83 by ($0.61). Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm had revenue of $3.03 billion during the quarter, compared to analyst estimates of $3.40 billion. During the same quarter in the previous year, the business earned $9.55 earnings per share. The business's quarterly revenue was down 3.7% compared to the same quarter last year. On average, sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th will be paid a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.67%. The ex-dividend date of this dividend is Tuesday, May 20th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is currently 8.96%.

Analyst Ratings Changes

A number of analysts have recently weighed in on the company. Piper Sandler dropped their price target on Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an "overweight" rating on the stock in a research report on Monday, January 27th. Guggenheim dropped their target price on Regeneron Pharmaceuticals from $940.00 to $810.00 and set a "buy" rating on the stock in a research report on Thursday, May 1st. JPMorgan Chase & Co. reduced their price target on shares of Regeneron Pharmaceuticals from $1,100.00 to $1,000.00 and set an "overweight" rating for the company in a report on Monday, March 31st. TD Cowen dropped their price objective on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a "buy" rating on the stock in a report on Tuesday, February 4th. Finally, StockNews.com downgraded shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Thursday, May 1st. One research analyst has rated the stock with a sell rating, five have issued a hold rating, eighteen have issued a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals currently has an average rating of "Moderate Buy" and an average target price of $892.60.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.